<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2669">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505647</url>
  </required_header>
  <id_info>
    <org_study_id>V211-042</org_study_id>
    <nct_id>NCT01505647</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)</brief_title>
  <official_title>A Phase III Double-Blinded, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Made With an Alternative Manufacturing Process (AMP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process
      [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to
      ZOSTAVAX™.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody</measure>
    <time_frame>Day 1 and Week 6 postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers</measure>
    <time_frame>Day 1 (Baseline) to Week 6 postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Adverse Experiences (AEs)</measure>
    <time_frame>Day 1 to Day 42 postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE is defined as any unfavorable and unintended change in the
structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination</measure>
    <time_frame>Day 1 to Day 42 postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination</measure>
    <time_frame>Day 1 to Day 182 postvaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">498</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Shingles</condition>
  <arm_group>
    <arm_group_label>ZOSTAVAX™ (AMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZOSTAVAX™ manufactured with an alternative process</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZOSTAVAX™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ZOSTAVAX™ manufactured with the current process</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zoster Vaccine, Live (AMP)</intervention_name>
    <description>One approximately 0.65-mL injection subcutaneously on Day 1</description>
    <arm_group_label>ZOSTAVAX™ (AMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zoster Vaccine, Live</intervention_name>
    <description>One approximately 0.65-mL injection subcutaneously on Day 1</description>
    <arm_group_label>ZOSTAVAX™</arm_group_label>
    <other_name>ZOSTAVAX™</other_name>
    <other_name>V211</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No fever on day of vaccination

          -  History of varicella or residence in a VZV-endemic area for ≥30 years

          -  Females of reproductive potential must have a negative pregnancy test and must agree
             to use acceptable methods of birth control

        Exclusion Criteria:

          -  History of hypersensitivity reaction to any vaccine component

          -  Prior receipt of any varicella or zoster vaccine

          -  Prior history of herpes zoster

          -  Have recently had another vaccination

          -  Pregnant or breastfeeding

          -  Use of immunosuppressive therapy

          -  Known or suspected immune dysfunction

          -  Concomitant antiviral therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 3, 2015</lastchanged_date>
  <firstreceived_date>January 4, 2012</firstreceived_date>
  <firstreceived_results_date>April 10, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant in the ZOSTAVAX™ (AMP) group was randomized but not vaccinated, making the number of participants vaccinated in this group 331</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZOSTAVAX™ (AMP)</title>
          <description>Zoster Vaccine, Live Alternative Manufacturing Process (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
        </group>
        <group group_id="P2">
          <title>ZOSTAVAX™</title>
          <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Day 1 Through Day 42 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Day 43 Through Day 182 Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="328"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZOSTAVAX™ (AMP)</title>
          <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
        </group>
        <group group_id="B2">
          <title>ZOSTAVAX™</title>
          <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="332"/>
                <measurement group_id="B2" value="166"/>
                <measurement group_id="B3" value="498"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62.9" spread="7.1"/>
                <measurement group_id="B2" value="62.4" spread="7.0"/>
                <measurement group_id="B3" value="62.8" spread="7.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="196"/>
                <measurement group_id="B2" value="99"/>
                <measurement group_id="B3" value="295"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="136"/>
                <measurement group_id="B2" value="67"/>
                <measurement group_id="B3" value="203"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody</title>
        <description>VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
        <time_frame>Day 1 and Week 6 postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis included all vaccinated participants except those who had protocol deviations that interfered with the assessment of antibody response, developed suspected varicella or herpes zoster rashes before blood sampling, or reported an exposure to varicella or herpes zoster</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX™ (AMP)</title>
            <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX™</title>
            <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="330"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody</title>
            <description>VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)</description>
            <units>Units/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 postvaccination; n = 330, 166</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="235.7" lower_limit="211.7" upper_limit="262.5"/>
                  <measurement group_id="O2" value="208.2" lower_limit="176.4" upper_limit="245.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 postvaccination; n = 320, 164</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="532.6" lower_limit="489.2" upper_limit="579.9"/>
                  <measurement group_id="O2" value="457.1" lower_limit="403.3" upper_limit="518.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis tested is that the GMT at Week 6 postvaccination with ZOSTAVAX™ (AMP) vaccine is non-inferior to that with the current process vaccine</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The GMT induced by ZOSTAVAX™ (AMP) vaccine is statistically non-inferior to that induced by the current process vaccine if the lower bound of the 95% confidence interval of the GMT ratio is &gt;0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance is 0.025 (1-sided). The P-value was not adjusted.</p_value_desc>
            <method>Longitudinal regression model</method>
            <method_desc>The analyzed GMT ratio, 95% confidence interval, and P-value were based on a longitudinal regression model adjusting for age and vaccination group</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers</title>
        <description>VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).</description>
        <time_frame>Day 1 (Baseline) to Week 6 postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis included all vaccinated participants except those who had protocol deviations that interfered with the assessment of antibody response, developed suspected varicella or herpes zoster rashes before blood sampling, or reported an exposure to varicella or herpes zoster.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX™ (AMP)</title>
            <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX™</title>
            <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="320"/>
                  <measurement group_id="O2" value="164"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers</title>
            <description>VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).</description>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" lower_limit="2.1" upper_limit="2.4"/>
                  <measurement group_id="O2" value="2.2" lower_limit="2.0" upper_limit="2.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The hypothesis tested was that ZOSTAVAX™ (AMP) induces an acceptable GMFR in VZV antibody titer from prevaccination to 6 weeks postvaccination</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance is 0.025 (1-sided). The P-value was not adjusted.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Adverse Experiences (AEs)</title>
        <description>An AE is defined as any unfavorable and unintended change in the
structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.</description>
        <time_frame>Day 1 to Day 42 postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis included all vaccinated participants with safety follow-up data. One participant in the AMP vaccine group was vaccinated but lost to follow-up without safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX™ (AMP)</title>
            <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX™</title>
            <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="330"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With One or More Adverse Experiences (AEs)</title>
            <description>An AE is defined as any unfavorable and unintended change in the
structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="205"/>
                  <measurement group_id="O2" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination</title>
        <description>An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement</description>
        <time_frame>Day 1 to Day 42 postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis included all vaccinated participants with safety follow-up data. One participant in the AMP vaccine group was vaccinated but lost to follow-up without safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX™ (AMP)</title>
            <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX™</title>
            <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="330"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination</title>
            <description>An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination</title>
        <description>An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement</description>
        <time_frame>Day 1 to Day 182 postvaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis included all vaccinated participants with safety follow-up data. One participant in the AMP vaccine group was vaccinated but lost to follow-up without safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX™ (AMP)</title>
            <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX™</title>
            <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="330"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination</title>
            <description>An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: Day 1 to Day 182 postvaccination; Other Adverse Events: Day 1 to Day 42 postvaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ZOSTAVAX™ (AMP)</title>
          <description>Zoster Vaccine, Live (AMP) : One approximately 0.65-mL injection subcutaneously on Day 1</description>
        </group>
        <group group_id="E2">
          <title>ZOSTAVAX™</title>
          <description>Zoster Vaccine, Live : One approximately 0.65-mL injection subcutaneously on Day 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired oesophageal web</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="138" subjects_affected="135" subjects_at_risk="330"/>
                <counts group_id="E2" events="68" subjects_affected="66" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="153" subjects_affected="146" subjects_at_risk="330"/>
                <counts group_id="E2" events="69" subjects_affected="68" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection-site pruritus</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="330"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="107" subjects_affected="106" subjects_at_risk="330"/>
                <counts group_id="E2" events="56" subjects_affected="53" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
